What question did this study set out to answer?

To evaluate the therapeutic efficacy, predictive response factors, recurrence rates, and survival outcomes of terlipressin administered with or without albumin in patients with hepatorenal syndrome.

October 1, 2002HepatologyOpen Access

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study

View Full Paper

Ask AI

Bookmark

Authors

RORolando OrtegaNational Instruments (Ireland)PGPere GinèsUniversité Paris-Sud JUJuan UrízComplejo Hospitalario de Navarra

Discussion

Member takes

Implication

A prospective nonrandomized study reveals that adding albumin to terlipressin boosts renal response in hepatorenal syndrome, highlighting the value of co-administration.

Key Points

To evaluate the therapeutic efficacy, predictive response factors, recurrence rates, and survival outcomes of terlipressin administered with or without albumin in patients with hepatorenal syndrome.
Prospective, nonrandomized study evaluating 21 consecutive patients with hepatorenal syndrome (16 type 1 HRS, 5 type 2 HRS).
Patients received intravenous terlipressin (0.5–2 mg every 4 hours) until complete response (serum creatinine < 1.5 mg/dL) or up to 15 days; 13 patients concomitantly received intravenous albumin.
Complete response occurred in 57% of patients overall (12/21), with albumin co-administration identified as the sole predictive factor of complete response (77% with terlipressin plus albumin vs. 25% with terlipressin alone, P = .03).
Terlipressin combined with albumin led to marked decreases in serum creatinine, increased arterial pressure, and suppression of the renin-aldosterone system, whereas terlipressin monotherapy showed no significant changes in these markers.
Recurrence of hepatorenal syndrome occurred in 17% of complete responders, achieving complete response was linked to improved survival, and only 1 patient experienced ischemic adverse events.

Cite This Study

Ortega et al. (2002) studied this question.

synapsesocial.com/papers/6a6f45998031ec7bb1dbad43 https://doi.org/10.1053/jhep.2002.35819

View Full Paper

Ask AI

Bookmark

Implication

A prospective nonrandomized study reveals that adding albumin to terlipressin boosts renal response in hepatorenal syndrome, highlighting the value of co-administration.

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study

Discussion

Member takes

Implication

Key Points

Cite This Study

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider